Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination

• Main Authors: Takahiro Niimura (Author), Mitsuhiro Goda (Author), Koji Miyata (Author), Jun Matsumoto (Author), Toshihiko Yoshioka (Author), Hirofumi Hamano (Author), Fuka Aizawa (Author), Kenta Yagi (Author), Yuki Izawa-Ishizawa (Author), Yoshito Zamami (Author), Keisuke Ishizawa (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Introduction: The combination of atezolizumab, an immune checkpoint inhibitor (ICI), and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is the first choice for systemic therapy in hepatocellular carcinoma. Immune-related cardiovascular toxicity-myocarditis and pericarditis-are k...